rs12547845

Variant summary

Our verdict is Benign. The variant received -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBA1

The NM_177924.5(ASAH1):​c.126-21A>G variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.479 in 1,467,130 control chromosomes in the GnomAD database, including 172,590 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).

Frequency

Genomes: 𝑓 0.43 ( 14933 hom., cov: 31)
Exomes 𝑓: 0.48 ( 157657 hom. )

Consequence

ASAH1
NM_177924.5 intron

Scores

2

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:6

Conservation

PhyloP100: -0.776

Publications

5 publications found
Variant links:
Genes affected
ASAH1 (HGNC:735): (N-acylsphingosine amidohydrolase 1) This gene encodes a member of the acid ceramidase family of proteins. Alternative splicing results in multiple transcript variants, at least one of which encodes a preproprotein that is proteolytically processed. Processing of this preproprotein generates alpha and beta subunits that heterodimerize to form the mature lysosomal enzyme, which catalyzes the degradation of ceramide into sphingosine and free fatty acid. This enzyme is overexpressed in multiple human cancers and may play a role in cancer progression. Mutations in this gene are associated with the lysosomal storage disorder, Farber lipogranulomatosis, and a neuromuscular disorder, spinal muscular atrophy with progressive myoclonic epilepsy. [provided by RefSeq, Oct 2015]
ASAH1 Gene-Disease associations (from GenCC):
  • ASAH1-related sphingolipidosis
    Inheritance: AR Classification: DEFINITIVE Submitted by: ClinGen
  • Farber lipogranulomatosis
    Inheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: G2P, Orphanet, Labcorp Genetics (formerly Invitae), Genomics England PanelApp
  • spinal muscular atrophy-progressive myoclonic epilepsy syndrome
    Inheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Labcorp Genetics (formerly Invitae), Orphanet, Genomics England PanelApp, G2P

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -20 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.83).
BP6
Variant 8-18071411-T-C is Benign according to our data. Variant chr8-18071411-T-C is described in ClinVar as Benign. ClinVar VariationId is 259277.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BA1
GnomAd4 highest subpopulation (AMR) allele frequency at 95% confidence interval = 0.519 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
ASAH1NM_177924.5 linkc.126-21A>G intron_variant Intron 2 of 13 ENST00000637790.2 NP_808592.2 Q13510-1Q53H01A8K0B6

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
ASAH1ENST00000637790.2 linkc.126-21A>G intron_variant Intron 2 of 13 1 NM_177924.5 ENSP00000490272.1 Q13510-1

Frequencies

GnomAD3 genomes
AF:
0.430
AC:
65227
AN:
151782
Hom.:
14917
Cov.:
31
show subpopulations
Gnomad AFR
AF:
0.276
Gnomad AMI
AF:
0.577
Gnomad AMR
AF:
0.529
Gnomad ASJ
AF:
0.619
Gnomad EAS
AF:
0.381
Gnomad SAS
AF:
0.523
Gnomad FIN
AF:
0.420
Gnomad MID
AF:
0.430
Gnomad NFE
AF:
0.487
Gnomad OTH
AF:
0.465
GnomAD2 exomes
AF:
0.494
AC:
104458
AN:
211334
AF XY:
0.497
show subpopulations
Gnomad AFR exome
AF:
0.272
Gnomad AMR exome
AF:
0.655
Gnomad ASJ exome
AF:
0.609
Gnomad EAS exome
AF:
0.366
Gnomad FIN exome
AF:
0.412
Gnomad NFE exome
AF:
0.488
Gnomad OTH exome
AF:
0.502
GnomAD4 exome
AF:
0.485
AC:
637842
AN:
1315230
Hom.:
157657
Cov.:
20
AF XY:
0.488
AC XY:
320838
AN XY:
657758
show subpopulations
African (AFR)
AF:
0.266
AC:
8133
AN:
30530
American (AMR)
AF:
0.638
AC:
26560
AN:
41652
Ashkenazi Jewish (ASJ)
AF:
0.610
AC:
15122
AN:
24804
East Asian (EAS)
AF:
0.403
AC:
15511
AN:
38506
South Asian (SAS)
AF:
0.538
AC:
43216
AN:
80262
European-Finnish (FIN)
AF:
0.412
AC:
21151
AN:
51288
Middle Eastern (MID)
AF:
0.488
AC:
2477
AN:
5076
European-Non Finnish (NFE)
AF:
0.485
AC:
479286
AN:
987894
Other (OTH)
AF:
0.478
AC:
26386
AN:
55218
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.479
Heterozygous variant carriers
0
13252
26504
39755
53007
66259
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
13658
27316
40974
54632
68290
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.430
AC:
65282
AN:
151900
Hom.:
14933
Cov.:
31
AF XY:
0.431
AC XY:
31960
AN XY:
74236
show subpopulations
African (AFR)
AF:
0.276
AC:
11440
AN:
41420
American (AMR)
AF:
0.529
AC:
8076
AN:
15266
Ashkenazi Jewish (ASJ)
AF:
0.619
AC:
2148
AN:
3472
East Asian (EAS)
AF:
0.382
AC:
1964
AN:
5146
South Asian (SAS)
AF:
0.525
AC:
2526
AN:
4816
European-Finnish (FIN)
AF:
0.420
AC:
4416
AN:
10526
Middle Eastern (MID)
AF:
0.429
AC:
126
AN:
294
European-Non Finnish (NFE)
AF:
0.487
AC:
33085
AN:
67934
Other (OTH)
AF:
0.461
AC:
975
AN:
2114
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.503
Heterozygous variant carriers
0
1765
3531
5296
7062
8827
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
608
1216
1824
2432
3040
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.473
Hom.:
3373
Bravo
AF:
0.434
Asia WGS
AF:
0.418
AC:
1453
AN:
3478

ClinVar

Significance: Benign
Submissions summary: Benign:6
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not provided Benign:3
Oct 22, 2015
Mayo Clinic Laboratories, Mayo Clinic
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

Jun 19, 2018
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. -

not specified Benign:1
-
PreventionGenetics, part of Exact Sciences
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Spinal muscular atrophy-progressive myoclonic epilepsy syndrome Benign:1
Jul 14, 2021
Genome-Nilou Lab
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Farber lipogranulomatosis Benign:1
Jul 14, 2021
Genome-Nilou Lab
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.83
CADD
Benign
1.0
DANN
Benign
0.79
PhyloP100
-0.78
Mutation Taster
=100/0
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.020
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs12547845; hg19: chr8-17928920; COSMIC: COSV50504232; COSMIC: COSV50504232; API